Commentary

Video

Single-dose faricimab in treatment-experiences eyes with nARMD: Case 2

Author(s):

Moritz Pettenkofer, MD

Moritz Pettenkofer, MD, presents a case of a 75-year-old male patient with nARMD who has had 53 injections of anti-VEGF therapy over 4 years.

Related Videos
Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Diana V. Do, MD: 3-Year PHOTON Data on Aflibercept 8 mg for DME | Image Credit: Stanford University
Eric W Schneider, MD: Comparing AI-Based Home OCT to In-Office OCT Scans | Image Credit: Tennessee Retina
Matthew Cunningham, MD: 1-Year ELEVATUM Results Target Disparities in DME | Image Credit: Florida Retina Institute
Dennis M. Marcus, MD , an expert on neovascular AMD
Dennis M. Marcus, MD , an expert on neovascular AMD
HCPLive Five at ASRS 2024 | Image Credit: HCPLive
Related Content
Sozinibercept Topline Results Expected in Q2 After COAST Trial Completion| Image Credit: Opthea
February 19th 2025

Sozinibercept Topline Results Expected in Q2 After COAST Trial Completion

Connor Iapoce
MEDcast logo
July 1st 2024

Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME

Hong-Uyen Hua, MD Sruthi Arepalli, MD Rishi P. Singh, MD
Ophthalmology Month in Review: January 2025 | Image Credit: HCPLive
February 6th 2025

Ophthalmology Month in Review: January 2025

Connor Iapoce
New Insight with Veeral Sheth, MD Podcast logo | Image Credit: HCPLive
June 11th 2024

New Insight: A Look at the OcuLenz with Michael Freeman, CEO of Ocutrx

Connor Iapoce
FDA Approves Susvimo for Diabetic Macular Edema | Image Credit: FDA
February 4th 2025

FDA Approves Susvimo for Diabetic Macular Edema

Connor Iapoce
ONS-5010 for Wet AMD Secures Noninferiority in NORSE EIGHT Trial | Image Credit: Wills Eye Hospital
January 19th 2025

ONS-5010 for Wet AMD Secures Noninferiority in NORSE EIGHT Trial

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.